Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Arcturus Therapeutics Holdings Inc. (“Arcturus” or the “Company”) (NASDAQ: ARCT). Such...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Mr. Cooper Group Inc. (“Mr. Cooper” or the “Company”) (NASDAQ: COOP). Such investors are...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH). Such...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Quanex Building Products Corporation (“Quanex” or the “Company”) (NYSE: NX)....
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Dow Inc. (“Dow” or the “Company”) (NYSE: DOW) and certain officers. The class...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against VF Corporation (“VFC” or the “Company”) (NYSE: VFC). Such investors are advised...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK)....
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH). Such...
-
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR). Such investors are...